Sociodemographic Factors Influenced Survival in Young Adults With Colorectal Cancer
In this study, a young adult was defined as an individual who was 40 years or younger.
American Society of Clinical Oncology Gastrointestinal (ASCO GI) Symposium
Study Reveals Differences Between the Genomic Profiles of Primary Tumors and Metastatic Lesions in Intrahepatic Cholangiocarcinoma
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
Prior Exposure to Antibiotics or Antacids Did Not Reduce Immunotherapy Response in Advanced HCC
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Addition of PEGPH20 to Frontline Chemotherapy Did Not Improve Clinical Outcomes in Pancreatic Cancer Subgroup
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
Tumor Size and Stiffness May Be Relevant Biomarkers of Response to ICIs in Hepatocellular Carcinoma
The median change in HCC tumor size between responders and nonresponders was statistically significant.
Avelumab Maintenance: No OS Benefit vs Continued Chemotherapy in HER2-Negative Gastrointestinal Cancers
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Use of Value Pathways to Guide Treatment Decisions in Gastric Cancer Had Little Impact on Overall Survival
Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.
Progression-Free Rate With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Associated With PD-L1 Level
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GI 2020
Loading... 
Loading...